Active clinical trials for "COVID-19"

To determine whether an individually prescribed homeopathic medicine has an effect greater than a placebo and is a viable treatment option to improve fatigue and quality of life for patients suffering from the symptoms of Post-acute COVID-19 Syndrome. The researchers hope to achieve this goal by conducting a clinical trial that is scientifically rigorous and clinically relevant. Expected results of this pilot study will be to obtain sufficient experience and preliminary feasibility data to justify a larger clinical trial of this hypothesis.

This is a study of the BinaxNOW Covid-19 Ag Card as a method to rapidly identify SARS-CoV-2 infection in asymptomatic children, teachers, and other school staff for exclusion. 240 students and 80 teachers in the Madison Metropolitan School District (MMSD) will be enrolled and can expect to be on study for up to 8 weeks.

The evolution of Coronavirus disease 2019 (COVID-19) pandemic makes it more necessary the intervention of Primary Health Care Physiotherapy Units in patients with respiratory and/or functional sequelae after suffering from SARS-CoV-2 (acute respiratory sindrome by coronavirus) virus infection. Since some months ago, Primary Health Care use telerehabilitation tools to connect patients and health care professions while maintaining social distancing and restrictions. Tele-physiotherapy is a field of physiotherapy which has the advantage of providing physical therapy interventions to patients' complications after COVID-19 by using a videoconferencing method. The aim of this study is to evaluate the effectiveness of a multimodal Physical Therapy telerehabilitation program in persistent post COVID-19 symptoms in Primary Health Care.

The main objective of this study is to evaluate the incidence of post-COVID morbidity and characterize the complications profile in patients who participated in the APLICOV-PC study. APLICOV-PC study was a multicenter, randomized, proof-of-concept clinical trial to assess the safety profile of 3 different dose levels of plitidepsin (1,5 mg, 2,0 mg and 2,5 mg) administered three consecutive days, in adult patients with confirmed diagnosis of COVID-19 who require hospital admission.

A randomized, double-blinded, placebo-controlled trial will be conducted to evaluate vortioxetine, an antidepressant with established pro-cognitive properties, for the treatment of cognitive deficits which develop during or after an infection consistent with COVID-19, continue for 2+ months, and are not explained by an alternative diagnosis (i.e., post-COVID-19 condition). Participants (aged 18-64 years) will receive vortioxetine (10-20 mg) or placebo for 8 weeks. Participants 65+ years will receive vortioxetine (5-10 mg) or placebo for 8 weeks. Changes in cognitive functioning from baseline to endpoint (week 8) will be assessed via the Digit Symbol Substitution Test (DSST). Study visits may be conducted remotely (e.g. via Zoom, by telephone), and/or in-person.

In December 2019, a cluster of pneumonia cases, caused by a newly identified βcoronavirus, occurred in Wuhan, China.1 The World Health Organization (WHO) officially named the disease as coronavirus disease 2019 (COVID-19), and the International Committee on Taxonomy of Viruses named the virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).2 On 11 March 2020, the WHO declared the epidemic of COVID-19 as a pandemic.3 The pandemic crisis prioritises critical care for those coronavirus (COVID-19) patients who have been most profoundly affected, and hospitals, staffing, and working practices have been radically adjusted to accommodate this.4,5 The healthcare industry, in particular, has been overwhelmed by the effect of COVID-19 on healthcare resources. This has been underscored by providers concerned about emotional strain and physical exhaustion, access to personal protective equipment (PPE) and medical equipment, workplace exposure to COVID-19 and disease transmission to family members.6 Physicians are essential for any health-care system and at the frontline defense against the COVID-19 pandemic. They play a crucial role in diagnosis, treatment, prevention of disease spread, and public education during this pandemic. Moreover, they are frequently exposed to infected individuals with COVID-19, making them at higher risk of infection than others.7 Anesthesia is one such specialty whose residents are uniquely at risk of exposure to infection in the operating room or ICU. Residents reported that their learning schedule is distorted in our hospital regarding skills because of increase ICU rotations, cancelled elective surgeries, missing one or two of the major rotations. Also, lecturers were stopped and replaced by E-learning after a long period. Examination schedule was changed and so the research schedule. Infection of the trainees (or a member of a family) had a great emotional and physical impact on them. COVID-19 will not go away any time soon, and therefore the new balance between service provision and training needs to be agreed in a sensitive way to avoid further frustration amongst trainees. Adaptations to these circumstances have delivered new forms of teaching and supervision. We design this cross-sectional study and implement a survey that included a 58-question to accomplish the specific aims of the present study through comparisons of two groups of residents and to provide plans for the training programme to be less affected by pandemics.

Treatment of dialysis patients involved with COVID-19 with short daily hemodialysis has been supposed to improve short term outcome. It is unclear if short daily dialysis would optimize mortality or ICU admission in routine dialysis patients with COVID-19. Also the potential variants according with worse outcomes remain to be fully elucidated.

This is Phase 2 multi-center controlled randomized study to assess the efficacy and safety of MIR 19® via 14 days of treatment of participants with symptomatic moderate COVID-19. The purpose of this study is to evaluate the efficacy, safety and daily dose of MIR 19 ® for the treatment of the hospitalized patients with infection caused by SARS-CoV-2 (COVID-19) who did not require treatment in the intensive care unit. Based on preclinical data studying antiviral effect of MIR 19® in vitro and in vivo (Khaitov M.R. et all 2021), the investigators hypothesized that SARS-CoV-2 inhibition with MIR 19® could potentially reduce pulmonary inflammation, thereby improving COVID-19 patient outcomes.

This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.

Preliminarily investigate the safety and efficacy of two doses of hzVSF-v13 + SOC vs. placebo + SOC for the treatment of COVID-19 pneumonia.